Cologaurd
If colorectal cancer is detected early, 90% of deaths are preventable. However, colorectal cancer does not cause symptoms in its earliest stage and arises spontaneously within the population of people who do not have a family history of cancer nor an inherited change in their DNA that would increase their risk. New science published in January 2022 showed that Cologuard can detect 92% of cases of colon cancer. However, it is NOT a substitute for a colonoscopy.
Colon cancer progresses slowly which makes it preventable and often curable. Ealy detection is vital to prevent disease and death.
A negative test means that the patient should continue to be screened at intervals recommended by their Gastroenterology Associates of Brooklyn specialist.
Studies report that 13% of people without colorectal cancer or advanced adenomas received a false positive result and 8% of patients with cancer got a false negative result.
Cologuard is indicated for use by adults aged 45 and older, who are at average risk of colon cancer. It is not for use by adults who are at high-risk. IT is not for adults who have any gastrointestinal symptoms.
A high-risk adult is one who has a personal history of colon cancer and adenomas, has had a positive colon cancer screening test within the past six month, has been diagnosed with conditions that create a high-risk such as inflammatory bowel disease, chronic ulcerative colitis, Crohn’s or a family history of colorectal cancer, polyps, or a hereditary syndrome that predisposes to colon cancer.
It is a prescription product that can be obtained from Gastroenterology Associates of Brooklyn.
Contact Gastroenterology Associates of Brooklyn to discuss your colon cancer screening options.